A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, a 5 mg dose of CP-690,550 will be given to study subjects on two separate occasions using one of two different strength tablets each time. The amount of CP-690,550 available in the blood following administration of each tablet will be measured and compared. The overall aim of the study is to establish that a similar amount of CP-690,550 is absorbed into the blood following administration of the same dose of each different strength tablet .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

NCT00517543

Chronic Obstructive Pulmonary Disease (COPD) Rheumatoid Arthritis Atherosclerosis

COMPLETED PHASE1

Bioequivalence Study of CJ-30060 in Healthy Volunteers

NCT03757390

Healthy Subjects

UNKNOWN PHASE1

Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

NCT04886050

Gout Hyperuricemia

COMPLETED PHASE1

BE Study in Patients - Methotrexate Tablets

NCT02940561

Psoriasis Rheumatoid Arthritis

UNKNOWN PHASE1

Bioequivalence Study of Generic Celecoxib 200 mg Capsules

NCT06337422

Healthy Volunteer

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a bioequivalence study for CP-690,550.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1

Group Type EXPERIMENTAL

Treatment A

Intervention Type DRUG

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Treatment B

Intervention Type DRUG

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

Sequence 2

Group Type EXPERIMENTAL

Treatment B

Intervention Type DRUG

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

Treatment A

Intervention Type DRUG

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment A

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Intervention Type DRUG

Treatment B

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

Intervention Type DRUG

Treatment B

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

Intervention Type DRUG

Treatment A

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>45 kg (99 lbs).
* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).

Exclusion Criteria

Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Personal or family history of hereditary immunodeficiency (eg, severe - Evidence of any clinically significant illness, medical condition, or disease.

* Evidence or history of any clinically significant infections within the past 3 months.
* Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes